CAUTION: Investigational device. Limited by Federal (United States) law to investigational use only.
reSept and atHeart Medical are registered trademarks of atHeart Medical.
© 2021 atHeart Medical. All Rights Reserved
ASD patients at heart
atHeart Medical aims to establish the first transcatheter ASD occluder with a metal-free frame as the new standard of care for atrial septal defects (ASDs).
The reSept™ ASD Occluder
With its metal-free frame and minimal footprint, patients have ‘less device’ permanently implanted
Reduce potential complications
Designed to reduce potential complications without limiting future transseptal interventions
Based in Switzerland and the U.S., we have assembled an exceptional team with decades of experience at medical device start-ups and major corporations.
We have initiated the ASCENT-ASD pivotal trial in the United States and internationally to demonstrate the safety and efficacy of our reSept ASD Occluder for treating patients with clinically significant, isolated ASD. Our reSept ASD Occluder has received Investigational Device Exemption approval from the U.S. FDA.
Our company was founded by the Olle Larsson Holding AG (OLH), a Swiss corporate group with a diverse portfolio of companies in medical devices, among other sectors. Our ASD occluder was initially developed by CARAG, a Swiss engineering and consulting firm, also an OLH company.
Our name embeds our values: in everything we do, we have clinical excellence and patients at heart.
We are problem solvers developing meaningful solutions for unmet clinical needs.
We work from “the heart” with a primary focus on our patients.
We cultivate collaboration and incorporate learnings from experience.